HRP20080559T3 - 2-(kinoksalin-5-ilsulfonilamino)-benzamidni spojevi kao regulatori cck2 - Google Patents

2-(kinoksalin-5-ilsulfonilamino)-benzamidni spojevi kao regulatori cck2

Info

Publication number
HRP20080559T3
HRP20080559T3 HR20080559T HRP20080559T HRP20080559T3 HR P20080559 T3 HRP20080559 T3 HR P20080559T3 HR 20080559 T HR20080559 T HR 20080559T HR P20080559 T HRP20080559 T HR P20080559T HR P20080559 T3 HRP20080559 T3 HR P20080559T3
Authority
HR
Croatia
Prior art keywords
4alkyl
phenyl
alkyl
group
carbon
Prior art date
Application number
HR20080559T
Other languages
English (en)
Croatian (hr)
Inventor
D. Allison Brett
D. Hack Michael
K. Phuong Victor
H. Rabinowitz Michael
D. Rosen Mark
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20080559T3 publication Critical patent/HRP20080559T3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/42Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20080559T 2003-08-08 2004-08-04 2-(kinoksalin-5-ilsulfonilamino)-benzamidni spojevi kao regulatori cck2 HRP20080559T3 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49407403P 2003-08-08 2003-08-08
PCT/US2004/025153 WO2005016896A1 (en) 2003-08-08 2004-08-04 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds as cck2 modulators

Publications (1)

Publication Number Publication Date
HRP20080559T3 true HRP20080559T3 (hr) 2009-01-31

Family

ID=34193199

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20080559T HRP20080559T3 (hr) 2003-08-08 2004-08-04 2-(kinoksalin-5-ilsulfonilamino)-benzamidni spojevi kao regulatori cck2

Country Status (33)

Country Link
US (3) US7304051B2 (pt)
EP (2) EP1651622B1 (pt)
JP (2) JP4818110B2 (pt)
KR (1) KR20060060007A (pt)
CN (2) CN1863782A (pt)
AR (1) AR045930A1 (pt)
AT (2) ATE403650T1 (pt)
AU (2) AU2004265312B2 (pt)
BR (1) BRPI0413449A (pt)
CA (2) CA2534887A1 (pt)
CR (1) CR8229A (pt)
CY (1) CY1106486T1 (pt)
DE (2) DE602004004663T2 (pt)
DK (2) DK1651622T3 (pt)
EA (1) EA200600203A1 (pt)
EC (1) ECSP066355A (pt)
ES (2) ES2310294T3 (pt)
HR (1) HRP20080559T3 (pt)
IL (1) IL173591A0 (pt)
IS (1) IS8280A (pt)
LT (1) LT5410B (pt)
LV (1) LV13453B (pt)
MX (2) MXPA06001550A (pt)
NO (1) NO20061122L (pt)
NZ (1) NZ545030A (pt)
PL (2) PL1651621T3 (pt)
PT (2) PT1651621E (pt)
SG (1) SG131114A1 (pt)
SI (2) SI1651622T1 (pt)
TW (1) TW200521120A (pt)
UA (1) UA84025C2 (pt)
WO (2) WO2005016897A1 (pt)
ZA (1) ZA200601946B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200600203A1 (ru) * 2003-08-08 2006-08-25 Янссен Фармацевтика, Н. В. Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
WO2005085188A2 (en) * 2004-03-02 2005-09-15 Compass Pharmaceuticals Llc Compounds and methods for anti-tumor therapy
US20050250829A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Kinase inhibitors
US7947833B2 (en) * 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
JP2008514608A (ja) * 2004-09-24 2008-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルホンアミド化合物
FR2904317A1 (fr) 2006-07-27 2008-02-01 Inst Nat Sante Rech Med Analogues d'halogenobenzamides marques a titre de radiopharmaceutiques
US8592565B2 (en) * 2007-01-12 2013-11-26 The Board Of Trustees Of The Leland Stanford Junior University Preparation of azide-modified carbon surfaces for coupling to various species
US8247403B2 (en) * 2007-03-07 2012-08-21 Takeda Pharmaceutical Company Limited Benzoxazepine derivatives and use thereof
WO2008124518A1 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
EP2131245A3 (en) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithographic apparatus and its focus determination method
WO2009154754A2 (en) * 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
US20100305093A1 (en) * 2009-04-09 2010-12-02 Exelixis, Inc. Inhibitors of mTOR and Methods of Making and Using
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
JP5815029B2 (ja) 2010-07-09 2015-11-17 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネル遮断薬としてのテトラゾール化合物
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン,インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
DK3345899T3 (da) 2012-03-01 2020-05-11 Allergan Inc Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン,インコーポレイテッド 三環式化合物ならびにその製造および使用方法
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
JP6361168B2 (ja) * 2013-06-17 2018-07-25 Jsr株式会社 液晶配向剤、液晶配向膜、液晶表示素子、液晶表示素子の製造方法、重合体及び化合物
CN103524386B (zh) * 2013-10-24 2016-05-18 江苏鼎龙科技有限公司 2-氨基-4-甲磺酰胺甲基苯甲酸甲酯的制备方法
CA2929858C (en) 2013-11-22 2022-03-29 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
KR20170016754A (ko) * 2015-08-04 2017-02-14 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN106565509A (zh) * 2016-11-03 2017-04-19 江苏鼎龙科技有限公司 2‑氨基‑4‑甲氨基苯甲酸甲酯盐酸盐的制备方法
KR101894091B1 (ko) * 2018-01-23 2018-08-31 씨제이헬스케어 주식회사 크로마논 유도체의 신규한 제조방법
CN108218806B (zh) * 2018-04-02 2019-03-01 上海馨远医药科技有限公司 一种n-叔丁氧羰基吗啉-3-羧酸的制备方法
CN111285806B (zh) * 2018-12-06 2022-04-15 中国医学科学院药物研究所 吡唑类化合物及其制备方法、用途和药物组合物
CN116675684B (zh) * 2023-08-02 2023-11-07 上海翰森生物医药科技有限公司 含炔基稠环类衍生物拮抗剂、其制备方法和应用
WO2025224201A1 (en) 2024-04-26 2025-10-30 F. Hoffmann-La Roche Ag Novel process for the synthesis of substituted morpholines and thiomorpholines
CN118878477B (zh) * 2024-05-31 2025-09-23 上海馨远医药科技有限公司 一种手性r或s的3-甲基吗啉的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200420D0 (en) * 1992-01-09 1992-02-26 James Black Foundation The Lim Amino acid derivatives
PT720601E (pt) 1993-08-10 2001-02-28 Black James Foundation Ligandos de receptores de gastrina e cck
ES2206754T3 (es) 1996-12-10 2004-05-16 Zeria Pharmaceutical Co., Ltd. Derivados de 1,5 - benzodiazepina.
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE10134721A1 (de) * 2001-07-17 2003-02-06 Bayer Ag Tetrahydrochinoxaline
ITTO20020674A1 (it) * 2002-07-26 2004-01-26 Rotta Research Lab Derivati antranilici ad attivita' anticolecistochininica (anti-cck-1), procedimento per la loro preparazione e loro uso farmaceutico
US6943170B2 (en) * 2002-11-14 2005-09-13 Bristol-Myers Squibb Company N-cycloalkylglycines as HIV protease inhibitors
EA200600203A1 (ru) * 2003-08-08 2006-08-25 Янссен Фармацевтика, Н. В. Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
JP2008514608A (ja) * 2004-09-24 2008-05-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルホンアミド化合物

Also Published As

Publication number Publication date
DE602004004663T2 (de) 2007-11-22
CN1863781A (zh) 2006-11-15
JP2007501841A (ja) 2007-02-01
EP1651622B1 (en) 2007-02-07
SI1651621T1 (sl) 2008-12-31
SG131114A1 (en) 2007-04-26
MXPA06001550A (es) 2006-09-04
CN1863782A (zh) 2006-11-15
PL1651622T3 (pl) 2007-07-31
CR8229A (es) 2008-09-10
EP1651621B1 (en) 2008-08-06
US20050038032A1 (en) 2005-02-17
CA2534885C (en) 2013-06-04
ECSP066355A (es) 2006-08-30
NO20061122L (no) 2006-05-04
DK1651622T3 (da) 2007-05-07
PT1651622E (pt) 2007-04-30
IL173591A0 (en) 2006-07-05
DE602004015614D1 (de) 2008-09-18
CY1106486T1 (el) 2012-01-25
AU2004265311A1 (en) 2005-02-24
JP4818110B2 (ja) 2011-11-16
DE602004004663D1 (de) 2007-03-22
ES2310294T3 (es) 2009-01-01
JP2007501842A (ja) 2007-02-01
IS8280A (is) 2006-01-31
MXPA06001482A (es) 2006-09-04
US20080076918A1 (en) 2008-03-27
EP1651622A1 (en) 2006-05-03
AR045930A1 (es) 2005-11-16
LT2006017A (en) 2006-11-27
LV13453B (en) 2007-02-20
US7563895B2 (en) 2009-07-21
US7304051B2 (en) 2007-12-04
EP1651621A1 (en) 2006-05-03
ATE403650T1 (de) 2008-08-15
UA84025C2 (en) 2008-09-10
KR20060060007A (ko) 2006-06-02
ATE353322T1 (de) 2007-02-15
DK1651621T3 (da) 2008-11-10
EA200600203A1 (ru) 2006-08-25
AU2004265312B2 (en) 2010-05-20
LT5410B (lt) 2007-03-26
WO2005016896A1 (en) 2005-02-24
US20050043310A1 (en) 2005-02-24
AU2004265312A1 (en) 2005-02-24
TW200521120A (en) 2005-07-01
SI1651622T1 (sl) 2007-06-30
US7288651B2 (en) 2007-10-30
ES2281834T3 (es) 2007-10-01
CA2534887A1 (en) 2005-02-24
CA2534885A1 (en) 2005-02-24
NZ545030A (en) 2009-08-28
PT1651621E (pt) 2008-09-30
PL1651621T3 (pl) 2009-01-30
WO2005016897A1 (en) 2005-02-24
BRPI0413449A (pt) 2006-10-17
ZA200601946B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
CY1111671T1 (el) Ετεροκυκλικη ενωση
CR8827A (es) Compuesto heterociclico fusionado
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
TW200833251A (en) Pesticidal compositions
AR057914A1 (es) Compuestos organicos de azufre y su uso
ATE387452T1 (de) Spiroverbindungen mit npy antagonistischer wirkung
AR069802A1 (es) Compuestos de carbamoilo como inhibidores de dgat1 190
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
AR044695A1 (es) Derivados de azolidina, utiles como herbicidas.
EA200300107A1 (ru) Кристаллические формы трет-бутиламиновой соли периндоприла
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
DOP2010000194A (es) Derivados de oxadiazol activos sobre fosfato de esfingosina-1
EA200200819A1 (ru) Кристаллическая форма ii линезолида
MY146663A (en) Organic sulfur compound and its use for controlling harmful arthropod
EA201000881A1 (ru) Пиридилметил-сульфонамидные соединения
CO6260016A2 (es) Uso de los compuestos de sulfoanilida como herbicida
ATE549922T1 (de) Biozidzusammensetzungen enthaltend 2- methylisothiazolin-3-on und ein haloalkylsulfon
EA200300927A1 (ru) Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов
HRP20110785T8 (en) Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands
MXPA06000185A (es) Derivados de quinazolinas 5-sustituidas.
DK0712395T3 (da) Fremgangsmåde til fremstilling af fluoralkenylthio-heterocykliske derivater
AR054386A1 (es) Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
CO5540303A2 (es) Derivados de 4-(fenil-piperidin-4-iliden-metil)-benzamida y su uso para el tratamiento del dolor, ansiedad o desordenes gastrointestinales